Sonja Kary

TL;DR: Patients treated with biologic agents have a higher a priori risk of infection, however, the data suggest that this risk is increased by treatment with tumor necrosis factor inhibitors.

TL;DR: Results of this prospective open-label study suggest that adalimumab had a substantial preventive effect on AU flares in patients with active AS, including patients with a recent history of AU flares.

TL;DR: Considering the limitations of an open-label study, adalimumab alone or in combination with standard DMARDs appeared to be well tolerated and effective in 6610 difficult-to-treat patients with active RA treated in clinical practice.

TL;DR: Younger age, greater CRP concentrations, HLA-B27 positivity, and TNF antagonist naivety were strongly associated with BASDAI 50, ASAS40, and partial remission responses, and important predictors of good clinical response were younger age and greater C-reactive protein (CRP) concentration.

TL;DR: Treatment continuation of biological agents in clinical practice is less likely than in randomised clinical trials but more likely in comparable controls treated with conventional DMARDs.